Universitätsklinikum Tübingen

3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) - Data from the RELIANCE Registry (2022) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Schuetz C, Kallinich T, et al. Conference contribution When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study (2022) Hampl M, Jaeger A, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution EARLY MANIFESTATION AND RAPID SYMPTOM PROGRESSION IN A CASE OF HOMOZYGOUS TRINUCLEOTIDE EXPANSION IN THE TBP-GENE IN AUTOSOMAL DOMINANT SPINOCEREBELLAR ATAXIA TYPE 17 (2022) Forras PV, Wilfling S, Mrochen A, Dufke C, Linker R, Hehr U, Kohl Z Conference contribution A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Factors associated with long-term survival after failure a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphomas:a role for allogeneic stem cell transplantation? (2022) Derigs P, Bethge W, Holtick U, Von Tresckow B, Ayuk F, Penack O, Vucinic V, et al. Conference contribution The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Buecklein , Mougiakakos D, Blumenberg , et al. Conference contribution Interprofessionelle Kommunikation uber,Complementary and Integrative Health" (CIH): Entwicklung und Implementierung eines Training-Programms (2022) Behzad A, Stein B, Schmitt A, Lohmuller L, Kroger B, Boltenhagen U, Joos S, et al. Conference contribution Community-level prevalence of epilepsy and of neurocysticercosis among people with epilepsy in the Balaka district of Malawi: A cross-sectional study (2022) Keller L, Stelzle D, Schmidt V, Carabin H, Reinhold AK, Keller C, Welte T, et al. Journal article Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution